A phase II study of gefitinib with concurrent thoracic radiotherapy in patients with unresectable, stage III Non-Small Cell Lung Cancer harboring EGFR mutations.
Phase of Trial: Phase II
Latest Information Update: 16 Aug 2016
At a glance
- Drugs Gefitinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 12 Aug 2016 Planned number of patients changed from 37 to 27.
- 01 Aug 2012 Status changed from not yet recruiting to recruiting as reported by University Hospital Medical Information Network - Japan.
- 12 Jul 2012 New trial record